



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on
March 4, 2003

Anita W. Magatti
Registered Representative

Signature

March 4, 2003
Date of Signature

RECEIVED

MAR 17 2003

TECH CENTER 1600/2900

PATENT
CASE CN01180K1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
Bernard R Neustadt et al :

For Patent For :
Adenosine A2a Receptor Antagonists :
Examiner: John M. Ford

Serial No.: 09/865,071 :
Art Unit: 1624

Filing Date: May 24, 2001 :
-----X-----

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. 1.97(c) OR (d)

Sir:

37 C.F.R. 1.97(c)

- 1.a. The information disclosure statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
 - (1) a final action under § 1.113, or
 - (2) a notice of allowance under § 1.311, whichever occurs first.
- 1.b. This statement is accompanied by the certification set forth below. OR
- 1.c. Applicant(s) elect to pay the fee of \$180.00 for the submission of this information disclosure statement.

37 C.F.R. 1.97(d)

- 2.a. The information disclosure statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.
- 2.b. This statement is accompanied by the certification set forth below. AND
- 2.c. Applicant(s) hereby petition for the consideration of the accompanying information disclosure statement. AND
- 2.d. The fee for this petition is \$130.00.

RECEIVED

MAR 17 2003

TECH CENTER 1600/2900

METHOD OF PAYMENT

- 3.a. Charge \$ 180.00 to Deposit Account No. 19-0365.
- 3.b. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0365.

CERTIFICATION

4. I, the person signing below, hereby certify
 that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
 that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of the statement.

Name _____

Signature _____

Date _____

Respectfully submitted,

Anita W. Magatti
Attorney/Agent for Applicant(s)
Registration No.: 29,825
Telephone No.: (908) 298-5067

SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Date: March 4, 2003



#6

PATENT
CASE CN01180K1IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
Bernard R Neustadt et al

For Patent For :
Adenosine A2a Receptor Antagonists

Serial No.: 09/865,071

Filing Date: May 24, 2001

RECEIVED
MAR 17 2003
TECH CENTER 1600/2900

Examiner: J. Ford
Art Unit: 1624Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530Assistant Commissioner for Patents
Washington, D.C. 20231SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98. Applicants enclose a Form PTO-1449 (1 page) listing an additional publication known to applicants that may be relevant to this application. This Statement is being submitted after three months from filing the application and after an action on the merits has been received. A transmittal form authorizing payment of the necessary fee accompanies this statement.

Publication BL discloses substituted [1,2,4]triazolo[1,5-c]pyrimidines differing from the instantly claimed compounds in the 5-position substituent in the pyrimidine portion and in the substitution on the pyrazolo ring portion ("A" in the reference).

It is noted that four of the references cited in applicants original IDS – AL, AN, AR, and the US equivalent to AM - were cited in the International Search Report of corresponding application PCT application WO 01/92264.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C., 20231, on March 4, 2003

Anita W. Magatti

Registered Representative

Signature


3/4/03
Date

-2-

A copy of the newly cited publication is attached.

The examiner is respectfully requested to examine the publications, initial the form PTO-1449 and return a copy of the initialed form to applicants.

Respectfully submitted,



Anita W. Magatti
Reg. No. 29,825
Attorney for Applicants
(908) 298-5067